THERAPY DOSSIER · th-edf72480367f

Hyaluronan tetrasaccharide (HA4)

Drug · No confident ChEMBL match; hyaluronan oligosaccharide (cytoprotective/HSP-inducing)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; hyaluronan oligosaccharide (cytoprotective/HSP-inducing)
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: HA4
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25373446 ↗2014Reported benefit

Hyaluronan tetrasaccharide exerts neuroprotective effect and promotes functional recovery after acute spinal cord injury in rats.

RatSpinal cord injuryUnspecifiedSprague-Dawley

Model: Acute spinal cord injury in rats (model details not stated in the abstract)

Hyaluronan tetrasaccharide improved locomotor and electrophysiological recovery after spinal cord injury and upregulated BDNF, VEGF, CD44 and TLR-4, with effects apparently mediated through CD44 and TLR-4.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…